In another study, the use of PI3K/Akt/mTOR pathway inhibitors in acute myeloid leukemia cells demonstrated the expression regulation of immunological checkpoint ligands and the interference in immune evasion mechanisms of leukemic cells, with a decrease in Programmed cell death protein 1 ligand (PD-L1) expression after treatment with PI3K (idelalisib) and mTOR (everolimus) inhibitors [86]. The gene discussed is MTOR; the disease is acute myeloid leukemia.